| 摘要 |
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to immunology, and can be used for the ex-vivo determination of the cancer treatment efficiency. For this purpose, a level of activated T-lymphocytes (CD3+ CD69+) in an organism is measured after the introduction to a subject of one or more doses of an immunogenic composition. The level of the activated T-lymphocytes (CD3+ CD69+) higher than approximately 10.4% testifies to the fact that the subject is such that demonstrates successful clinical outcome for treatment; that is an increase of the survival rate.EFFECT: application of the level of the activated T-lymphocytes (CD3+ CD69+) makes it possible to apply them as a biomarker for the monitoring, modification or correction of cancer treatment.7 cl, 1 ex, 2 dwg |
